Sinusoidal obstruction syndrome (SOS) is a severe complication of hematopoietic stem cell transplantation (HSCT). SOS is characterized by painful hepatomegaly, jaundice, ascites, fluid retention and weight gain. 1 Prior exposure to gemtuzumab ozogamicin (GO) is recognized as a significant pre-transplant risk factor for the development of severe SOS after HSCT. 2 It has also been shown that patients who undergo HSCT shortly after being treated with GO (within 3.5 months) are at greatest risk of SOS. 2 Although defibrotide (DF) has been shown to be effective as a prophylaxis against and treatment for SOS, 3 it is not yet available for routine clinical use in Japan. Recombinant human soluble thrombomodulin (rTM), which comprises the active extracellular domain of thrombomodulin, inactivates coagulation by binding to thrombin. 4 A recent phase III trial examining the efficacy and safety of rTM showed that it significantly improved disseminated intravascular coagulation (DIC) associated with hematological malignancies or infections. 5 rTM also exhibits anti-inflammatory activity due to its ability to dampen proinflammatory mediator activity. 6 Recently, a few case reports have described that rTM is effective against SOS in adult patients. 7, 8 However, little is known about its usefulness for prophylaxis of rTM in the patients who are at high risk of SOS. Here, we report the cases of four patients who received HSCT shortly after GO treatment with or without prophylactic rTM.
Between April 2010 and December 2015, two males and two females (median age, 3 years; range, 1-13 years) with relapsed or refractory AML were treated with fludarabine, cytarabine, G-CSF and GO [FLAG-IDA-GO] as re-induction therapy prior to HSCT (Table 1 ). The protocol involved 30 mg/m 2 of fludarabine and 2 g/m 2 of cytarabine (days 2-6), 10 mg/m 2 of idarubicin (day 6) and 300 μg/m 2 of G-CSF (days 1-6). GO was administered at a dose of 3 mg/m 2 on day 7 of treatment. All patients except patient 1 (M7) had AML subtype M2 according to the French-AmericanBritish classification. Of these patients, patient 2 had primary refractory AML, and the other three patients (patients 1, 3 and 4) relapsed o 12 months after the initial diagnosis. All patients achieved CR after the FLAG-IDA-GO treatment. The median interval between the GO treatment and day 0 of the HSCT was 51 days (range, 36-79 days). Patient 1 underwent a haploidentical HSCT from his father. The other three patients (patients 2, 3 and 4) underwent unrelated cord blood transplants from HLA-2 or -3 locus-mismatched donors. All of the patients except patient 1 received full-intensity conditioning cyclophosphamide (120 mg/kg) per TBI (12 Gy) (patients 2, 3 and 4). Patient 1 received busulfan (19.2 mg/kg), melphalan (6 mg/kg) and fludarabine (4 mg/kg) due to his age (1 year). The prophylaxis for GvHD consisted of tacrolimus (0.02 mg/kg/day) and short-term methotrexate (days 1, 3 and 6: 7.5, 5 and 5 mg/m 2 , respectively). Ursodeoxycholic acid and low MW heparin (LMWH) were administered as prophylactic treatments against SOS in cases 1 and 2. The other patients received prophylactic rTM (380 U/kg per day for 7 days, from days 7 to 13) as well as ursodeoxycholic acid and LMWH as prophylactic treatments against SOS because patients 1 and 2 developed SOS around day 10. SOS was defined according to the modified Seattle criteria. 9 The severity grading of a suspected SOS (mild, moderate, severe and very severe) was determined based on new EBMT criteria. 10 In case 1, mild SOS developed on day 10, but it was successfully treated with rTM (380 U/kg for 7 days). In case 2, very severe SOS developed on day 8. Patient 2 was treated with rTM (380 U/kg), but it failed to improve her SOS. Therefore, continuous hemodiafiltration was initiated to manage the patient's water levels and remove any inflammatory cytokines. As a result, her SOS gradually improved. No SOS was seen in the patients who received prophylactic rTM (patients 3 and 4), nor did they suffer any adverse effects of the rTM, for example, excess bleeding. Patients 3 and 4 exhibited normal peak plasma levels of plasminogen activator inhibitor-1 (PAI-1), which is used as a diagnostic marker of SOS. Three patients (patients 2, 3 and 4) were alive and in remission at 58, 32 and 13 months, respectively. Patient 1 died of his primary disease at 12 months after the HSCT.
The limited findings of this study suggest that SOS prophylaxis with rTM is feasible in GO-treated patients undergoing HSCT. GO is a humanized anti-CD33 Ab conjugated to the cytotoxic agent calicheamicin. The use of GO before HSCT raises the risk of SOS because it binds to CD33 on sinusoidal ECs, inducing vasoconstriction and hepatocyte necrosis. 11 In particular, some studies have suggested that patients who undergo allo-HSCT shortly after GO treatment (within 3.5 months) are at markedly increased risk of SOS.
2 Therefore, clinicians should try to delay HSCT after GO treatment. However, this is not always feasible because the outcomes of HSCT for pediatric relapsed AML during the second CR (2CR) are good, 12 and it is sometimes necessary to perform HSCT as soon as possible to achieve a 2CR. For these reasons, all of our patients received HSCT less than 3.5 months after GO treatment.
DF has been shown to be effective as a prophylaxis against SOS. 3 Recently developed guidelines recommend prophylactic DF for children that are at high risk of SOS. 13 Versluys et al. 14 reported that DF successfully prevents SOS in patients that undergo HSCT after GO treatment. In the current study, two patients who only received ursodeoxycholic acid and LMWH as prophylactic treatments against SOS developed SOS. The next two patients received rTM as a prophylaxis against SOS since DF can not be used clinically in Japan.
rTM was developed as a drug treatment for DIC in Japan. 5 It increased the antithrombin III activity levels and decreased the PAI-1 levels of patients with DIC, suggesting that rTM might help to protect endothelial cells (ECs) from injury. As the pathogenesis of SOS is based on EC damage, rTM is considered to be useful for protecting against SOS. As reported previously, rTM has also been successfully used to rescue individuals from SOS. 7, 8 Nomura et al.
15
reported that 14 days' prophylactic rTM starting on day 7 of HSCT significantly decreased the levels of inflammatory cytokines, such as interleukin-6, in HSCT recipients compared with those of patients treated with prophylactic heparin. Since SOS commonly occurs around day 10 of HSCT 1 , prophylactic rTM was used from days 7 to 13 (1 week) in the present study. Both ursodeoxycholic acid and LMWH were continued after the start of the rTM therapy. While the two patients who did not receive prophylactic rTM developed SOS, the two patients who were treated with prophylactic rTM did not, and their PAI-1 levels did not change. Therefore, rTM might prevent endothelial damage. The prophylactic use of rTM could help to prevent the development of SOS in individuals who receive HSCT after GO treatment. However, there is limited information available about the prophylactic use of rTM against SOS, and several issues, such as the recommended duration and dosage of prophylactic rTM, remain unclear.
In conclusion, prophylactic rTM might have a beneficial role in the prevention of SOS in patients who are at high risk of developing the condition, such as those who have previously been treated with GO. However, no confirmed conclusion can be made because of the very small number of patients. Therefore, further prospective studies are required to determine the efficacy and optimal duration and dosage of prophylactic rTM.
